



DATE: August 6, 2014

TO: Whom it may concern

FROM: Deborah Thomas, MD
Associate Professor
Department of Leukemia
Telephone 713-745-4616
Facsimile 713-794-4297
E-mail debthomas@mdanderson.org

RE: ABUABARA, SANDY CAMILA (DOB 04/12/1989)
MR #1055578

DIAGNOSIS: Relapsed/refractory B-lymphoblastic leukemia

SUBJECT: VISA

This is to confirm that Sandy Camila Abuabara has been under my care at the MD Anderson Cancer Center for her diagnosis of relapsed/refractory B-lymphoblastic leukemia since 02/27/2014. Camila has undergone several different chemotherapy treatments since that time, unfortunately not yet achieving a remission of the leukemia.


She most notably recently commenced a new experimental treatment with a continuous infusion of a monoclonal antibody (blinatumomab) via a specialized clinical trial after being hospitalized on 07/24/14. Sandy was reevaluated by me on 08/05/14 after being discharged from the hospital on 08/04/14 and appears to be tolerating the treatment well thus far, but will be completing several months of this treatment if she responds as expected, with the hope of proceeding to allogeneic stem cell transplantation thereafter with curative intent.

There are several cycles of treatment anticipated, and each cycle of the treatment occurs over a 4 week period (where the treatment is given intravenously continuously for the entire cycle), repeated every 6 weeks (after a two week hiatus), because of the need for minimal interruption in order to achieve/maintain the response. The preliminary results of this agent in other clinical trials has been very impressive and the hope is that Camila will indeed achieve a remission with this treatment. A significant effort was launched in order to gain entry into and proceed with the clinical trial.

Please afford Camila every consideration with respect to the necessity for her to remain in the United States in order to continue this potentially life-saving leukemia treatment via this clinical trial. It is imperative that she continues with the treatment and must do so here under the auspices of the MD Anderson Cancer Center as this agent is not available commercially.

Please do not hesitate to contact me for any questions or clarifications you might require. I can best be reached by e-mail in most instances.

Sincerely,

A handwritten signature in black ink, appearing to read "Deborah Thomas". The signature is fluid and cursive, with a large initial "D" and "T".

Deborah Thomas, MD
Associate Professor
Department of Leukemia